調査レポートカテゴリー： MarketsandMarkets, 世界, 医療/バイオ

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) - Global Forecast to 2027

局所薬物送達のグローバル市場予測

◆タイトル：Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) - Global Forecast to 2027
◆商品コード：PH7545-22
◆調査・発行会社：MarketsandMarkets
◆発行日：2022年5月26日
◆ページ数：297
◆レポート形式：PDF / 英語
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：グローバル
◆産業分野：医薬品
◆販売価格オプション（消費税別）

Single User（1名様閲覧）	USD4,950 ⇒換算￥0	見積依頼/購入/質問フォーム
Multi User (Five User)	USD6,650 ⇒換算￥0	見積依頼/購入/質問フォーム
Corporate License (全社内共有可)	USD8,150 ⇒換算￥0	見積依頼/購入/質問フォーム

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※商品の納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。（振込先：三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。（但し、対応範囲は弊社で判断）
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

マーケッツアンドマーケッツ社は、世界の局所薬物送達市場規模が、2022年2,074億ドルから2027年3,178億ドルまで年平均8.9％成長すると予測しています。本調査レポートでは、局所薬物送達の世界市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、種類別（半固体、固体、液体、経皮製品）分析、投与経路別（皮膚、眼、膣、直腸、鼻）分析、使用施設別（在宅医療、病院＆クリニック、火傷治療センター、その他）分析、地域別分析、競争状況、企業情報などの項目を掲載しています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・世界の局所薬物送達市場規模：種類別（半固体、固体、液体、経皮製品）
・世界の局所薬物送達市場規模：投与経路別（皮膚、眼、膣、直腸、鼻）
・世界の局所薬物送達市場規模：使用施設別（在宅医療、病院＆クリニック、火傷治療センター、その他）
・世界の局所薬物送達市場規模：地域別
・競争状況
・企業情報

“The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%.”
The growth of this market can largely be attributed to the high prevalence of topical prescription therapy for dry eye diseases, growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, increase in prevalence of central nervous disorders, rising preference for non-invasive drug delivery methods.

“The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, based on product in 2021.”
Based on products, the topical drug delivery the market is segmented into semi-solid formulations, liquid formulations, solid formulations, and transdermal products. The large share of semi-solid formulations segment is attributed to better patient adherence with limited side effects, more absorption, provide efficiency in drug release, and does not harm the gastrointestinal tract.

“Dermal drug delivery accounted for the largest share of the market.”
Based on the route of administration, the market is segmented into dermal, ophthalmic, rectal, vaginal, and nasal drug delivery. The large share of the dermal drug delivery market segment can largely be attributed to accessible product launches and adoption as they have fewer regulatory requirements, enhancement of penetrations and permeation of drugs as they are delivered through skin, and less irritation in patients as compared to nasal or ophthalmic drug delivery.

“Home care settings hold the largest share in the market, by facility of use”
Based on the facility of use, the market is segmented into home care settings, hospitals & clinics, burn centers, and other facilities. The large share of home care settings segment can be attributed to better patient comfort, growing awareness regarding home care settings is improving patient acceptability, decline in hospital visits due to COVID-19 pandemic, and shift in trend from treatments carried out in hospitals and nursing homes to treatments at home due to cost-effectiveness of home care settings.

“The APAC to witness the highest growth during the forecast period.”
Asia Pacific is expected to grow at the highest CAGR during the forecast period of 2022–2027. The high incidence of skin diseases (such as skin cancer), the rising prevalence of chronic diseases (such as diabetes), increasing use of contraceptives, the increasing geriatric population, and the growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems are some of the major factors that are expected to drive the growth of the topical drug delivery market in the Asia Pacific region.

Break of primary participants was as mentioned below:
• By Company Type – Tier 1–35%, Tier 2–45%, and Tier 3–20%
• By Designation – C-level–35%, Director-level–25%, Others–40%
• By Region – North America–45%, Europe–30%, Asia Pacific–20%, Latin America- 3%, Middle East and Africa–2%

Key players in the Topical Drug Delivery Market
The prominent players in the topical drug delivery market are Glenmark Pharmaceuticals Ltd. (India), Galderma (Switzerland), Johnson & Johnson Private Limited (US), GlaxoSmithKline Plc. (UK), Bausch Health Companies Inc. (Canada), Hisamitsu Pharmaceuticals Inc. (Japan), Cipla (India), Bayer AG (Germany), Viatris Inc. (Mylan N.V.) (US), 3M (US), Merck & Co.Inc.. (Germany), Crescita Therpeautics Inc. (Canada), Novartis International AG (Switzerland), Boehringer Ingelheim International GmBH (Germany), Pfizer Inc. (US), Teva Pharmaceuticals Industries Ltd. (Israel), Bristol Myers Squibb (US), Lead Chemical Co., Ltd. (Japan), Purdue Pharma L.P. (US), Lavipharm (Greece), AbbVie Inc. (US), CMP Pharma, Inc. (Germany), Encore Dermatology, Inc. (US), Prosolus Inc. (US), and Rusan Pharma Ltd. (India).

Research Coverage:
The report analyzes the topical drug delivery market and aims at estimating the market size and future growth potential of this market based on various segments such as product, route of administration, facility of use, and region. The report also includes a product portfolio matrix of various topical drug delivery products available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.

Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:
• Market Penetration: Comprehensive information on product portfolios offered by the top players in the topical drug delivery market. The report analyzes this market by product, by route of administration, and by facility of use.
• Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global topical drug delivery market
• Market Development: Comprehensive information on the lucrative emerging markets by product, route of administration, and facility of use
• Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global topical drug delivery market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global topical drug delivery market.

【レポートの目次】

1 INTRODUCTION 36
1.1 STUDY OBJECTIVES 36
1.2 MARKET DEFINITION AND SCOPE 36
1.2.1 INCLUSIONS & EXCLUSIONS 36
1.2.2 MARKETS COVERED 37
FIGURE 1 TOPICAL DRUG DELIVERY MARKET SEGMENTATION 37
1.2.3 YEARS CONSIDERED 37
1.3 CURRENCY 38
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 38
1.4 STAKEHOLDERS 38
1.5 SUMMARY OF CHANGES 39
2 RESEARCH METHODOLOGY 40
2.1 RESEARCH DATA 40
FIGURE 2 RESEARCH DESIGN 40
2.1.1 SECONDARY DATA 41
2.1.1.1 Key data from secondary sources 42
2.1.2 PRIMARY DATA 42
FIGURE 3 PRIMARY SOURCES 42
2.1.2.1 Key data from primary sources 43
2.1.2.2 Key industry insights 44
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE
AND DEMAND SIDE PARTICIPANTS 44
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE PARTICIPANTS 45
2.2 MARKET SIZE ESTIMATION 45
FIGURE 6 MARKET SIZE APPROACH: REVENUE SHARE ANALYSIS 46
FIGURE 7 TOPICAL DRUG DELIVERY MARKET – REVENUE SHARE
ANALYSIS ILLUSTRATION: JOHNSON & JOHNSON 46
FIGURE 8 PHARMACEUTICAL SALES APPROACH 47
FIGURE 9 TOP-DOWN APPROACH 48
FIGURE 10 CAGR PROJECTIONS 49
FIGURE 11 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
IN TOPICAL DRUG DELIVERY MARKET (2022–2027): IMPACT
ON MARKET GROWTH & CAGR 49
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 50
FIGURE 12 DATA TRIANGULATION METHODOLOGY 51
2.4 MARKET SHARE ANALYSIS 52
2.5 STUDY ASSUMPTIONS 52
2.6 LIMITATIONS 53
2.6.1 METHODOLOGY-RELATED LIMITATIONS 53
2.6.2 SCOPE-RELATED LIMITATIONS 53
2.7 RISK ASSESSMENT 53
TABLE 2 RISK ASSESSMENT: TOPICAL DRUG DELIVERY MARKET 53
3 EXECUTIVE SUMMARY 54
FIGURE 13 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2022 VS. 2027 (USD BILLION) 54
FIGURE 14 TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION,
2022 VS. 2027 (USD BILLION) 55
FIGURE 15 TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2022 VS. 2027 (USD BILLION) 56
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF TOPICAL DRUG DELIVERY MARKET 57
4 PREMIUM INSIGHTS 58
4.1 TOPICAL DRUG DELIVERY MARKET OVERVIEW 58
FIGURE 17 HIGH PREVALENCE OF SKIN DISEASES AND HIGH INCIDENCE
OF BURN INJURIES TO DRIVE MARKET GROWTH 58
4.2 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT AND COUNTRY (2021) 59
FIGURE 18 SEMI-SOLID FORMULATIONS TO DOMINATE
LATIN AMERICA MARKET IN 2021 59
4.3 TOPICAL DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 60
FIGURE 19 INDIA TO REGISTER HIGHEST GROWTH IN MARKET
DURING FORECAST PERIOD 60
4.4 TOPICAL DRUG DELIVERY MARKET, BY REGION (2020–2027) 61
FIGURE 20 NORTH AMERICA TO DOMINATE MARKET IN 2027 61
4.5 TOPICAL DRUG DELIVERY MARKET: DEVELOPED VS. DEVELOPING MARKETS 61
FIGURE 21 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH
RATES DURING FORECAST PERIOD 61
5 MARKET OVERVIEW 62
5.1 INTRODUCTION 62
5.2 MARKET DYNAMICS 62
TABLE 3 TOPICAL DRUG DELIVERY MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES 62
5.2.1 DRIVERS 63
5.2.1.1 High prevalence of skin diseases 63
5.2.1.2 Increase in self-medication as a popular practice in dermatology 64
5.2.1.3 High prevalence of topical prescription therapy for dry eye diseases 64
5.2.1.4 Switching from conventional needle injections to
transdermal patches 65
5.2.1.5 High incidence of burn injuries 65
5.2.1.6 Growing prevalence of diabetes 66

5.2.2 RESTRAINTS 66
5.2.2.1 Continuous irritation of skin and allergies caused by topical drugs 66
5.2.2.2 Preference for alternative modes of drug delivery 67
5.2.3 OPPORTUNITIES 67
5.2.3.1 Rising demand for self-administration and home care 67
5.2.3.2 Delivery of biologics through transdermal route 67
5.2.3.3 Topical vehicles used in cosmetic industry 68
5.2.4 CHALLENGES 68
5.2.4.1 Topical formulations for drugs with limited plasma concentration 68
5.2.4.2 Increasing number of drug failures and product recalls 69
5.3 INDUSTRY TRENDS 69
5.3.1 NEW ADVANCEMENT IN TRANSDERMAL DRUG DELIVERY SYSTEM 69
5.3.2 ADOPTION OF TELEDERMATOLOGY 70
5.4 KEY CONFERENCES & EVENTS IN 2022-2023 70
TABLE 4 TOPICAL DRUG DELIVERY MARKET: DETAILED LIST OF
CONFERENCES & EVENTS 70
5.5 IMPACT OF COVID-19 71
5.6 REGULATORY ANALYSIS 72
TABLE 5 REGULATORY SCENARIO, BY COUNTRY 72
5.7 VALUE CHAIN ANALYSIS 75
FIGURE 22 TOPICAL DRUG DELIVERY MARKET: VALUE CHAIN ANALYSIS 75
5.8 ECOSYSTEM MAPPING 76
FIGURE 23 PHARMACEUTICAL DRUG DELIVERY MARKET ECOSYSTEM 76
5.9 TECHNOLOGY ANALYSIS 76
5.10 PRICING ANALYSIS 77
TABLE 6 REGIONAL PRICING ANALYSIS OF TOPICAL DRUGS, 2021 (USD) 77
5.11 PORTER’S FIVE FORCES ANALYSIS 78
TABLE 7 TOPICAL DRUG DELIVERY MARKET: PORTER’S FIVE FORCES ANALYSIS 78
5.11.1 THREAT OF NEW ENTRANTS 78
5.11.2 THREAT OF SUBSTITUTES 79
5.11.3 BARGAINING POWER OF SUPPLIERS 79
5.11.4 BARGAINING POWER OF BUYERS 79
5.11.5 INTENSITY OF COMPETITIVE RIVALRY 79
5.12 PATENT ANALYSIS 79
5.12.1 PATENT PUBLICATION TRENDS FOR TOPICAL DRUG DELIVERY 80
FIGURE 24 PATENT PUBLICATION TRENDS (JANUARY 2011– APRIL 2022) 80
5.12.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 80
FIGURE 25 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS)
FOR TOPICAL DRUG DELIVERY PATENTS (JANUARY 2011–APRIL 2022) 81
FIGURE 26 TOP APPLICANT COUNTRIES/REGIONS FOR TOPICAL DRUG DELIVERY (JANUARY 2011–APRIL 2022) 82
TABLE 8 LIST OF PATENTS/PATENT APPLICATIONS IN TOPICAL
DRUG DELIVERY MARKET, 2021–2022 82
6 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT 84
6.1 INTRODUCTION 85
TABLE 9 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION) 85
6.2 SEMI-SOLID FORMULATIONS 86
TABLE 10 KEY TOPICAL DRUG DELIVERY SEMI-SOLID FORMULATIONS AVAILABLE 86
TABLE 11 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 87
TABLE 12 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS,
BY COUNTRY, 2020–2027 (USD BILLION) 87
6.2.1 OINTMENTS 88
6.2.1.1 Ointments to be widely used in analgesic indications 88
TABLE 13 TOPICAL DRUG DELIVERY MARKET FOR OINTMENTS, BY COUNTRY,
2020–2027 (USD BILLION) 88
6.2.2 CREAMS 89
6.2.2.1 Creams to be most widely used formulation due to better absorption 89
TABLE 14 TOPICAL DRUG DELIVERY MARKET FOR CREAMS, BY COUNTRY,
2020–2027 (USD BILLION) 90
6.2.3 LOTIONS 90
6.2.3.1 Easy administration of lotions to drive demand 90
TABLE 15 TOPICAL DRUG DELIVERY MARKET FOR LOTIONS, BY COUNTRY,
2020–2027 (USD BILLION) 91
6.2.4 GELS 91
6.2.4.1 Faster drug release and greater patient acceptability to
drive gels market 91
TABLE 16 TOPICAL DRUG DELIVERY MARKET FOR GELS, BY COUNTRY,
2020–2027 (USD BILLION) 92
6.2.5 PASTES 92
6.2.5.1 Topical pastes to treat and prevent skin irritation 92
TABLE 17 TOPICAL DRUG DELIVERY MARKET FOR PASTES, BY COUNTRY,
2020–2027 (USD BILLION) 93
6.3 LIQUID FORMULATIONS 93
TABLE 18 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 94
TABLE 19 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY COUNTRY, 2020–2027 (USD BILLION) 94
TABLE 20 KEY LIQUID FORMULATIONS AVAILABLE 95
6.3.1 SUSPENSIONS 95
6.3.1.1 Higher rate of bioavailability and controlled onset of action to support market growth 95
TABLE 21 TOPICAL DRUG DELIVERY MARKET FOR SUSPENSIONS, BY COUNTRY,
2020–2027 (USD BILLION) 96
6.3.2 SOLUTIONS 96
6.3.2.1 Topical solutions with soluble chemicals to dissolve in various solvents 96
TABLE 22 TOPICAL DRUG DELIVERY MARKET FOR SOLUTIONS, BY COUNTRY,
2020–2027 (USD BILLION) 97
6.4 SOLID FORMULATIONS 97
TABLE 23 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 98
TABLE 24 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY COUNTRY, 2020–2027 (USD BILLION) 98
TABLE 25 KEY SOLID FORMULATIONS AVAILABLE 99
6.4.1 POWDERS 99
6.4.1.1 Inexpensive manufacturing and effectiveness against antifungal infections to propel powders market 99
TABLE 26 TOPICAL DRUG DELIVERY MARKET FOR POWDERS, BY COUNTRY,
2020–2027 (USD BILLION) 100
6.4.2 SUPPOSITORIES 100
6.4.2.1 Suppositories require suitable base to ensure drug
compatibility and stability 100
TABLE 27 TOPICAL DRUG DELIVERY MARKET FOR SUPPOSITORIES
, BY COUNTRY, 2020–2027 (USD BILLION) 101
6.5 TRANSDERMAL PRODUCTS 102
TABLE 28 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION) 102
TABLE 29 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY COUNTRY, 2020–2027 (USD BILLION) 103
TABLE 30 KEY TRANSDERMAL PRODUCTS AVAILABLE 103
6.5.1 TRANSDERMAL PATCHES 104
6.5.1.1 Transdermal patches to offer increased drug permeability across skin 104
TABLE 31 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES,
BY COUNTRY, 2020–2027 (USD BILLION) 105
6.5.2 TRANSDERMAL SEMI-SOLIDS 105
6.5.2.1 Transdermal semi-solids to offer fast drying on application site 105
TABLE 32 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL SEMI-SOLIDS,
BY COUNTRY, 2020–2027 (USD BILLION) 106
7 TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION 107
7.1 INTRODUCTION 108
TABLE 33 TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION,
2020–2027 (USD BILLION) 108
7.2 DERMAL DRUG DELIVERY 109
7.2.1 NANO-SIZED DRUG CARRIER SYSTEMS TO BE STUDIED TO
OVERCOME DRUG PENETRATION LIMITATION 109
TABLE 34 DERMAL DRUG DELIVERY MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 110
7.3 OPHTHALMIC DRUG DELIVERY 110
7.3.1 MICROEMULSION-BASED FORMULATIONS LEAD TO
BETTER OCULAR DRUG ADSORPTION 110
TABLE 35 OPHTHALMIC DRUG DELIVERY MARKET, BY COUNTRY,
2020–2027 (USD BILLION) 112
7.4 VAGINAL DRUG DELIVERY 112
7.4.1 RICH AND COMPLEX NETWORK OF CAPILLARIES OF
UPPER VAGINA TO CREATE SYSTEMIC DRUG DELIVERY SYSTEM 112
TABLE 36 VAGINAL DRUG DELIVERY MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 113
7.5 RECTAL DRUG DELIVERY 114
7.5.1 RECTAL ADMINISTRATION TO ENABLE BOTH LOCAL AND
SYSTEMIC THERAPY OF DRUGS 114
TABLE 37 RECTAL DRUG DELIVERY MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 115
7.6 NASAL DRUG DELIVERY 116
7.6.1 NASAL DELIVERY ROUTE OFFERS QUICK ONSET OF DRUG
ACTION AND CONVENIENCE AS COMPARED TO PARENTERAL ROUTE 116
TABLE 38 NASAL DRUG DELIVERY MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 117
8 TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE 118
8.1 INTRODUCTION 119
TABLE 39 TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020–2027 (USD BILLION) 119
8.2 HOMECARE SETTINGS 119
8.2.1 HOMECARE TO DOMINATE MARKET DURING FORECAST PERIOD 119
TABLE 40 TOPICAL DRUG DELIVERY MARKET FOR HOMECARE SETTINGS,
BY COUNTRY, 2020–2027 (USD BILLION) 121
8.3 HOSPITALS & CLINICS 121
8.3.1 TOPICAL ANAESTHETICS TO BE ADOPTED FOR VARIOUS MEDICAL AND SURGICAL SUB-SPECIALTIES 121
TABLE 41 TOPICAL DRUG DELIVERY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2020–2027 (USD BILLION) 122
8.4 BURN CENTERS 123
8.4.1 TOPICAL ANTIMICROBIAL FORMULATIONS FOR BURN-RELATED INJURIES TO DRIVE MARKET GROWTH 123
TABLE 42 TOPICAL DRUG DELIVERY MARKET FOR BURN CENTERS, BY COUNTRY,
2020–2027 (USD BILLION) 124
8.5 OTHER FACILITIES 124
TABLE 43 TOPICAL DRUG DELIVERY MARKET FOR OTHER FACILITIES, BY COUNTRY, 2020–2027 (USD BILLION) 125
9 TOPICAL DRUG DELIVERY MARKET, BY REGION 126
9.1 INTRODUCTION 127
FIGURE 27 TOPICAL DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 127
TABLE 44 TOPICAL DRUG DELIVERY MARKET, BY REGION, 2020–2027 (USD BILLION) 128
9.2 NORTH AMERICA 128
FIGURE 28 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET SNAPSHOT 129
TABLE 45 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY,
2020–2027 (USD BILLION) 130
TABLE 46 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2027 (USD BILLION) 130
TABLE 47 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 130
TABLE 48 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 131
TABLE 49 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 131
TABLE 50 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION) 131
TABLE 51 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 132
TABLE 52 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION) 132
9.2.1 US 133
9.2.1.1 Rising prevalence of skin diseases alongside approval and launch of innovative topical formulations to propel market growth 133
TABLE 53 US: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION) 134
TABLE 54 US: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 134
TABLE 55 US: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 134
TABLE 56 US: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 135
TABLE 57 US: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY TYPE, 2020–2027 (USD BILLION) 135
TABLE 58 US: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 135
TABLE 59 US: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION) 136
9.2.2 CANADA 136
9.2.2.1 Rising prevalence of hypertension and funding for topical drugs research to drive market growth 136
TABLE 60 CANADA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION) 137
TABLE 61 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 137
TABLE 62 CANADA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 137
TABLE 63 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 138
TABLE 64 CANADA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION) 138
TABLE 65 CANADA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 138
TABLE 66 CANADA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020–2027 (USD BILLION) 139
9.3 EUROPE 139
TABLE 67 RECENT DEVELOPMENTS IN EUROPEAN TOPICAL DRUG DELIVERY MARKET, 2019–2022 140
TABLE 68 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY,
2020–2027 (USD BILLION) 141
TABLE 69 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2027 (USD BILLION) 141
TABLE 70 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 142
TABLE 71 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 142
TABLE 72 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 142
TABLE 73 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION) 143
TABLE 74 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 143
TABLE 75 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020–2027 (USD BILLION) 143
9.3.1 GERMANY 144
9.3.1.1 Growing focus of pharmaceutical companies on topical products development and increasing target diseases to drive market growth 144
TABLE 76 DEVELOPMENTS AND PRODUCT LAUNCHES IN TOPICAL DRUG DELIVERY IN GERMANY, 2019–2022 144
TABLE 77 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2027 (USD BILLION) 145
TABLE 78 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 145
TABLE 79 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 145
TABLE 80 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 146
TABLE 81 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION) 146
TABLE 82 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 146
TABLE 83 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020–2027 (USD BILLION) 147
9.3.2 UK 147
9.3.2.1 Increasing developments by top players and demand for pain-free treatment to drive market growth 147
TABLE 84 UK: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2027 (USD BILLION) 148
TABLE 85 UK: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 148
TABLE 86 UK: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 149
TABLE 87 UK: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 149
TABLE 88 UK: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY TYPE, 2020–2027 (USD MILLION) 149
TABLE 89 UK: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 150
TABLE 90 UK: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020–2027 (USD BILLION) 150
9.3.3 FRANCE 150
9.3.3.1 Rising prevalence of diabetes and increasing geriatric population to support market growth 150
TABLE 91 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2027 (USD BILLION) 151
TABLE 92 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 151
TABLE 93 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 152
TABLE 94 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 152
TABLE 95 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION) 152
TABLE 96 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 153
TABLE 97 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020–2027 (USD BILLION) 153
9.3.4 ITALY 153
9.3.4.1 Rising number of smokers to propel transdermal patches demand 153
TABLE 98 ITALY: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2027 (USD BILLION) 154
TABLE 99 ITALY: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 154
TABLE 100 ITALY: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 155
TABLE 101 ITALY: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 155
TABLE 102 ITALY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY TYPE, 2020–2027 (USD BILLION) 155
TABLE 103 ITALY: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 156
TABLE 104 ITALY: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020–2027 (USD BILLION) 156
9.3.5 SPAIN 156
9.3.5.1 Growing diabetic patients to drive market growth 156
TABLE 105 SPAIN: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2027 (USD BILLION) 157
TABLE 106 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 158
TABLE 107 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 158
TABLE 108 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 158
TABLE 109 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION) 159
TABLE 110 SPAIN: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 159
TABLE 111 SPAIN: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020–2027 (USD BILLION) 160
9.3.6 SWITZERLAND 160
9.3.6.1 Rising geriatric population and emerging players focusing on topical drugs development to drive market growth 160
TABLE 112 SWITZERLAND: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2027 (USD BILLION) 161
TABLE 113 SWITZERLAND: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 161
TABLE 114 SWITZERLAND: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 162
TABLE 115 SWITZERLAND: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 162
TABLE 116 SWITZERLAND: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION) 162
TABLE 117 SWITZERLAND: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 163
TABLE 118 SWITZERLAND: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION) 163
9.3.7 REST OF EUROPE 163
TABLE 119 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2027 (USD BILLION) 164
TABLE 120 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 165
TABLE 121 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 165
TABLE 122 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 165
TABLE 123 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION) 166
TABLE 124 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 166
TABLE 125 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION) 167
9.4 ASIA PACIFIC 167
FIGURE 29 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET SNAPSHOT 168
TABLE 126 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY,
2020–2027 (USD BILLION) 169
TABLE 127 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2027 (USD BILLION) 169
TABLE 128 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, BY TYPE, 2020–2027 (USD BILLION) 170
TABLE 129 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 170
TABLE 130 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 170
TABLE 131 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION) 171
TABLE 132 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 171
TABLE 133 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION) 172
9.4.1 CHINA 172
9.4.1.1 Prevalence of diabetes and increase in pharmaceutical R&D investments to drive market growth 172
TABLE 134 CHINA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2027 (USD BILLION) 173
TABLE 135 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, BY TYPE, 2020–2027 (USD BILLION) 173
TABLE 136 CHINA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 173
TABLE 137 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 174
TABLE 138 CHINA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION) 174
TABLE 139 CHINA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 174
TABLE 140 CHINA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020–2027 (USD BILLION) 175
9.4.2 JAPAN 175
9.4.2.1 Increasing number of product approvals and growing focus of local players on topical formulations R&D to support market growth 175
TABLE 141 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2027 (USD BILLION) 176
TABLE 142 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, BY TYPE, 2020–2027 (USD BILLION) 176
TABLE 143 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 176
TABLE 144 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 177
TABLE 145 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION) 177
TABLE 146 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 177
TABLE 147 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020–2027 (USD BILLION) 178
9.4.3 INDIA 178
9.4.3.1 Rising awareness among healthcare providers and patients alongside increasing focus on noninvasive methods of drug delivery to drive market growth 178
TABLE 148 INDIA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2027 (USD BILLION) 179
TABLE 149 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, BY TYPE, 2020–2027 (USD BILLION) 179
TABLE 150 INDIA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 180
TABLE 151 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 180
TABLE 152 INDIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY TYPE, 2020–2027 (USD MILLION) 180
TABLE 153 INDIA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 181
TABLE 154 INDIA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020–2027 (USD BILLION) 181
9.4.4 AUSTRALIA 181
9.4.4.1 Increasing number of smokers to drive market growth 181
TABLE 155 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2027 (USD BILLION) 182
TABLE 156 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 182
TABLE 157 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 183
TABLE 158 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 183
TABLE 159 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION) 183
TABLE 160 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 184
TABLE 161 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020–2027 (USD BILLION) 184
9.4.5 REST OF ASIA PACIFIC 184
TABLE 162 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION) 185
TABLE 163 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 186
TABLE 164 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 186
TABLE 165 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 186
TABLE 166 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION) 187
TABLE 167 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 187
TABLE 168 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET,
BY FACILITY OF USE, 2020–2027 (USD BILLION) 187
9.5 LATIN AMERICA 188
TABLE 169 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY,
2020–2027 (USD BILLION) 188
TABLE 170 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2027 (USD BILLION) 189
TABLE 171 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, BY TYPE, 2020–2027 (USD BILLION) 189
TABLE 172 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 189
TABLE 173 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 190
TABLE 174 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION) 190
TABLE 175 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 190
TABLE 176 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION) 191
9.5.1 BRAZIL 191
9.5.1.1 High prevalence of diabetes to propel market growth 191
TABLE 177 BRAZIL: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2027 (USD BILLION) 192
TABLE 178 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, BY TYPE, 2020–2027 (USD BILLION) 192
TABLE 179 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 192
TABLE 180 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 193
TABLE 181 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION) 193
TABLE 182 BRAZIL: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 193
TABLE 183 BRAZIL: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020–2027 (USD BILLION) 194
9.5.2 MEXICO 194
9.5.2.1 Increasing prevalence of glaucoma to drive market growth 194
TABLE 184 MEXICO: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2027 (USD BILLION) 195
TABLE 185 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, BY TYPE, 2020–2027 (USD BILLION) 195
TABLE 186 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 195
TABLE 187 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2020–2027 (USD BILLION) 196
TABLE 188 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION) 196
TABLE 189 MEXICO: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 196
TABLE 190 MEXICO: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020–2027 (USD BILLION) 197
9.5.3 REST OF LATIN AMERICA 197
TABLE 191 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION) 198
TABLE 192 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 198
TABLE 193 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 199
TABLE 194 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 199
TABLE 195 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION) 199
TABLE 196 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET,
BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 200
TABLE 197 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET,
BY FACILITY OF USE, 2020–2027 (USD BILLION) 200
9.6 MIDDLE EAST & AFRICA 200
9.6.1 GROWING PREVALENCE OF BURN INJURIES AND INCREASING EXPENDITURE ON HEALTHCARE TO DRIVE MARKET GROWTH 200
TABLE 198 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION) 201
TABLE 199 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR
SEMI-SOLID FORMULATIONS, BY TYPE, BY TYPE, 2020–2027 (USD BILLION) 201
TABLE 200 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 202
TABLE 201 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION) 202
TABLE 202 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 202
TABLE 203 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION) 203
TABLE 204 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION) 203
10 COMPETITIVE LANDSCAPE 204
10.1 OVERVIEW 204
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 204
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS 205
10.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 206
FIGURE 30 REVENUE ANALYSIS OF TOP PLAYERS IN TOPICAL DRUG DELIVERY MARKET 207
10.4 MARKET SHARE ANALYSIS 207
FIGURE 31 TOPICAL DRUG DELIVERY MARKET SHARE, BY KEY PLAYER, 2021 208
TABLE 205 TOPICAL DRUG DELIVERY MARKET: DEGREE OF COMPETITION 208
10.5 COMPETITIVE LEADERSHIP MAPPING 210
10.5.1 STARS 210
10.5.2 EMERGING LEADERS 210
10.5.3 PERVASIVE PLAYERS 210
10.5.4 PARTICIPANTS 210
FIGURE 32 TOPICAL DRUG DELIVERY MARKET: COMPETITIVE
LEADERSHIP MAPPING (2021) 211
10.6 COMPETITIVE LEADERSHIP MAPPING FOR OTHER PLAYERS 211
10.6.1 PROGRESSIVE COMPANIES 211
10.6.2 DYNAMIC COMPANIES 212
10.6.3 STARTING BLOCKS 212
10.6.4 RESPONSIVE COMPANIES 212
FIGURE 33 TOPICAL DRUG DELIVERY MARKET: COMPETITIVE LEADERSHIP
MAPPING FOR OTHER PLAYERS (2021) 212
10.7 COMPANY FOOTPRINT 213
TABLE 206 COMPANY FOOTPRINT: TOPICAL DRUG DELIVERY MARKET 213
10.7.1 PRODUCT FOOTPRINT OF MAJOR PLAYERS 214
TABLE 207 PRODUCT FOOTPRINT: TOPICAL DRUG DELIVERY MARKET (2021) 214
10.7.2 ROUTE OF ADMINISTRATION FOOTPRINT OF TOPICAL
DRUG DELIVERY MARKET 215
TABLE 208 ROUTE OF ADMINISTRATION FOOTPRINT:
TOPICAL DRUG DELIVERY MARKET (2021) 215
10.7.3 FACILITY OF USE IN TOPICAL DRUG DELIVERY MARKET 216
TABLE 209 FACILITY OF USE FOOTPRINT: TOPICAL DRUG DELIVERY MARKET (2021) 216
10.7.4 GEOGRAPHIC FOOTPRINT OF MAJOR PLAYERS IN TOPICAL
DRUG DELIVERY MARKET 217
TABLE 210 GEOGRAPHIC FOOTPRINT: TOPICAL DRUG DELIVERY MARKET (2021) 217
10.8 COMPETITIVE SCENARIO 218
10.8.1 PRODUCT LAUNCHES 218
TABLE 211 PRODUCT LAUNCHES, JANUARY 2019–APRIL 2022 218
10.8.2 DEALS 219
TABLE 212 DEALS, JANUARY 2019–APRIL 2022 219
10.8.3 OTHER DEVELOPMENTS 221
TABLE 213 OTHER DEVELOPMENTS, JANUARY 2019–APRIL 2022 221

11 COMPANY PROFILES 222
11.1 KEY PLAYERS 222
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
11.1.1 GLENMARK PHARMACEUTICALS LTD. 222
TABLE 214 GLENMARK PHARMACEUTICALS LTD.: BUSINESS OVERVIEW 222
FIGURE 34 GLENMARK PHARMACEUTICALS LTD.: COMPANY SNAPSHOT (2021) 223
11.1.2 GALDERMA 227
TABLE 215 GALDERMA: BUSINESS OVERVIEW 227
11.1.3 JOHNSON & JOHNSON PRIVATE LIMITED 231
TABLE 216 JOHNSON & JOHNSON PRIVATE LIMITED: BUSINESS OVERVIEW 231
FIGURE 35 JOHNSON & JOHNSON PRIVATE LIMITED: COMPANY SNAPSHOT (2021) 232
11.1.4 GLAXOSMITHKLINE PLC. 236
TABLE 217 GLAXOSMITHKLINE PLC: BUSINESS OVERVIEW 236
FIGURE 36 GLAXOSMITHKLINE, PLC.: COMPANY SNAPSHOT (2021) 237
11.1.5 BAUSCH HEALTH COMPANIES INC. 241
TABLE 218 BAUSCH HEALTH COMPANIES INC.: BUSINESS OVERVIEW 241
FIGURE 37 BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT (2021) 242
11.1.6 HISAMITSU PHARMACEUTICAL CO., INC. 248
TABLE 219 HISAMITSU PHARMACEUTICAL CO., INC.: BUSINESS OVERVIEW 248
FIGURE 38 HISAMITSU PHARMACEUTICAL CO., INC.: COMPANY SNAPSHOT (2021) 249
11.1.7 CIPLA 251
TABLE 220 CIPLA: BUSINESS OVERVIEW 251
FIGURE 39 CIPLA: COMPANY SNAPSHOT (2021) 252
11.1.8 BAYER AG 256
TABLE 221 BAYER AG: BUSINESS OVERVIEW 256
FIGURE 40 BAYER AG: COMPANY SNAPSHOT (2021) 257
11.1.9 VIATRIS INC. (MYLAN N.V.) 259
TABLE 222 VIATRIS INC.: BUSINESS OVERVIEW 259
FIGURE 41 VIATRIS INC.: COMPANY SNAPSHOT (2021) 260
11.1.10 3M 263
TABLE 223 3M: BUSINESS OVERVIEW 263
FIGURE 42 3M: COMPANY SNAPSHOT (2021) 264
11.1.11 MERCK & CO., INC. 266
TABLE 224 MERCK & CO., INC.: BUSINESS OVERVIEW 266
FIGURE 43 MERCK & CO., INC.: COMPANY SNAPSHOT (2021) 267
11.1.12 CRESCITA THERAPEUTICS INC. 269
TABLE 225 CRESCITA THERAPEUTICS INC.: BUSINESS OVERVIEW 269
FIGURE 44 CRESCITA THERAPEUTICS INC.: COMPANY SNAPSHOT (2021) 270
11.1.13 NOVARTIS INTERNATIONAL AG 273
TABLE 226 NOVARTIS INTERNATIONAL: BUSINESS OVERVIEW 273
FIGURE 45 NOVARTIS INTERNATIONAL AG: COMPANY SNAPSHOT (2021) 274
11.1.14 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 276
TABLE 227 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: BUSINESS OVERVIEW 276
FIGURE 46 BOEHRINGER INGELHEIM INTERNATIONAL GMBH:
COMPANY SNAPSHOT (2021) 277
11.1.15 PFIZER INC. 278
TABLE 228 PFIZER INC.: BUSINESS OVERVIEW 278
FIGURE 47 PFIZER INC.: COMPANY SNAPSHOT (2021) 279
11.1.16 TEVA PHARMACEUTICAL INDUSTRIES LTD. 282
TABLE 229 TEVA PHARMACEUTICAL INDUSTRIES LTD.: BUSINESS OVERVIEW 282
FIGURE 48 TEVA PHARMACEUTICALS: COMPANY SNAPSHOT (2021) 283
11.1.17 BRISTOL MYERS SQUIBB 286
TABLE 230 BRISTOL MYERS SQUIBB: BUSINESS OVERVIEW 286
FIGURE 49 BRISTOL MYERS SQUIBB: COMPANY SNAPSHOT (2021) 287
11.1.18 LEAD CHEMICAL CO., LTD. 288
TABLE 231 LEAD CHEMICAL CO., LTD.: BUSINESS OVERVIEW 288
11.1.19 PURDUE PHARMA L.P. 289
TABLE 232 PURDUE PHARMA L.P.: BUSINESS OVERVIEW 289
11.1.20 LAVIPHARM 290
TABLE 233 LAVIPHARM: BUSINESS OVERVIEW 290
11.1.21 ABBVIE INC. 291
TABLE 234 ABBVIE INC.: BUSINESS OVERVIEW 291
FIGURE 50 ABBVIE INC.: COMPANY SNAPSHOT (2021) 292

11.2 OTHER PLAYERS 294
11.2.1 CMP PHARMA, INC. 294
11.2.2 ENCORE DERMATOLOGY, INC. 295
11.2.3 PROSOLUS INC. 296
11.2.4 RUSAN PHARMA LTD. 297
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
12 APPENDIX 298
12.1 INSIGHTS FROM INDUSTRY EXPERTS 298
12.2 DISCUSSION GUIDE 299
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 304
12.4 AVAILABLE CUSTOMIZATIONS 306
12.5 RELATED REPORTS 306
12.6 AUTHOR DETAILS 307

★調査レポート[局所薬物送達のグローバル市場予測] ( Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) - Global Forecast to 2027 / PH7545-22) 販売に関する免責事項

[局所薬物送達のグローバル市場予測] ( Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) - Global Forecast to 2027 / PH7545-22) についてEメールでお問い合わせ

◆関連調査資料◆

医薬品用包装機の世界市場予測（～2027）：製品別、種類別
PH2224-22 / MarketsandMarkets / 2022年3月28日 / マーケッツアンドマーケッツ社は、世界の医薬品用包装機市場規模が、2022年84億ドルから2027年119億ドルまで年平均7.2％成長すると予測しています。本調査資料では、医薬品用包装機の世界市場を調査対象とし、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品別（一次包装機、二次包装機、ラベリング＆シリアル化機器）分析、種類別（液体用包装機、固体用包装機、半固体用包装機、その他）分析、地域別分析、競争状況、企業情報などの項目を掲載しています。・イントロダクション・調査手法・エグゼクティブサマリー・プレミアムインサイト・市場概要・世界の医薬品用包装機市場規模：製品別（一次包装機、二次包装機、ラベリング＆シリアル化機器）・世界の医薬品用包装機市場規模：種類別（液体用包装機、固体用包装機、半固体用包装機、その他）・世界の医薬品用包装機市場規模：地域別・競争状況...“The global pharmaceutical packaging equipment market is projected to reach USD 11.9 Billion by 2027 from USD 8.4 Billion in 2022, at a CAGR of 7.2% from 2022 to 2027.” The growth of the global pharmaceutical packaging equipment market is driven by the rapidly growing generic & biopharmaceutical markets, growth in OTC drug sales, rising need for flexible and integrated packaging equipment, increased offshore manufacturing in the pharmaceuticals market, the introduction of regulatory standards on the packaging, and stringent norms against counterfeiting. However, factors such as the adoption of refurbished packaging equipment and the high cost of packaging equipment are...

3D細胞培養のグローバル市場予測
BT4414-22 / MarketsandMarkets / 2022年5月25日 / マーケッツアンドマーケッツ社は、世界の3D細胞培養市場規模が、2022年13億ドルから2027年26億ドルまで年平均15.6％成長すると予測しています。本調査レポートでは、3D細胞培養の世界市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、種類別（足場あり3D細胞培養、足場なし3D細胞培養、マイクロ流体ベース3D細胞培養、磁気＆バイオプリント3D細胞培養）分析、用途別（癌＆幹細胞研究、創薬＆毒性試験、組織工学＆再生医療）分析、エンドユーザー別（製薬＆バイオテクノロジー企業、研究機関、化粧品産業、その他）分析、地域別分析、競争状況、企業情報などの項目を掲載しています。・イントロダクション・調査手法・エグゼクティブサマリー・プレミアムインサイト・市場概要・世界の3D細胞培養市場規模：種類別（足場あり3D細胞培養、足場なし3D細胞培養、マイクロ流体ベース3D細胞培養、磁気＆バイオプリント3D細胞培養）・世界の3D細胞培養市場規模：用途別（癌＆幹細胞研究、創薬＆毒性試験、組織工学＆再生医療）・世界の3D細胞培養市場規模：エンドユーザー別（製薬＆バイオテクノロジー企業、研究機関、化粧品産業、その他）・世界の3D細胞培養市場規模：地域別...“The global 3D cell culture market is valued at an estimated USD 1.3 billion in 2022 and is projected to reach USD 2.6 billion by 2027, at a CAGR of 15.6% during the forecast period.” The growth of this market is mainly driven by factors such as the increasing focus on developing alternative methods to animal testing, growing focus on personalized medicine, increasing incidence of chronic diseases, and the availability of funding for research. On the other hand, a lack of infrastructure for 3D cell-based research and the high cost of cell biology research are expected to restrain the growth...

高薬理活性原薬（HPAPI）のグローバル市場予測
PH4897-22 / MarketsandMarkets / 2022年5月17日 / マーケッツアンドマーケッツ社は、世界の高薬理活性原薬（HPAPI）市場規模が、2022年245億ドルから2027年396億ドルまで年平均10.1％成長すると予測しています。本調査レポートでは、高薬理活性原薬（HPAPI）の世界市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、HPAPI分類・概要、種類別（革新的HPAPI、ジェネリックHPAPI）分析、合成タイプ別（合成、バイオテクノロジー）分析、メーカータイプ別（キャプティブ、マーチャント）分析、用途別（腫瘍、ホルモン不均衡、緑内障、その他）分析、地域別分析、競争状況、企業情報などの項目を掲載しています。・イントロダクション・調査手法・エグゼクティブサマリー・プレミアムインサイト・市場概要・HPAPI分類・概要・世界の高薬理活性原薬（HPAPI）市場規模：種類別（革新的HPAPI、ジェネリックHPAPI）・世界の高薬理活性原薬（HPAPI）市場規模：合成タイプ別（合成、バイオテクノロジー）・世界の高薬理活性原薬（HPAPI）市場規模：メーカータイプ別（キャプティブ、マーチャント）...“The HPAPI market is projected to reach USD 39.6 Billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027.” The market is driven by increasing demand for oncology drugs, growing demand for antibody-drug conjugates and others. “The innovative HPAPIs segment is expected to account for the largest share of the market in 2021” Based on type, the HPAPI market is segmented into innovative and generic. The innovative segment is expected to account for the largest share of the HPAPI market in 2021. The large share can be attributed to the increased R&D...

世界の医薬品添加剤市場予測：製品別、機能性別、製剤別
PH3047 / MarketsandMarkets / 2021年3月18日 / マーケッツアンドマーケッツ社は、世界の医薬品添加剤市場規模が2021年79億ドルから2026年106億ドルまで、年平均5.8%成長すると予測しています。本調査資料では、医薬品添加剤の世界市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、産業洞察、製品別（有機化学物質、無機化学物質、その他）分析、機能性別（充填剤・希釈剤、懸濁剤・粘度剤、コーティング剤、結合剤、香料・甘味料）分析、製剤別（経口製剤、局所製剤、非経口製剤、その他）分析、地域別分析、競争状況、企業情報などを掲載しています。・イントロダクション・調査手法・エグゼクティブサマリー・プレミアムインサイト・市場概要・産業洞察・世界の医薬品添加剤市場規模：製品別（有機化学物質、無機化学物質、その他）・世界の医薬品添加剤市場規模：機能性別（充填剤・希釈剤、懸濁剤・粘度剤、コーティング剤、結合剤、香料・甘味料）・世界の医薬品添加剤市場規模：製剤別（経口製剤、局所製剤、非経口製剤、その他）...“The pharmaceutical excipeints market is projected to reach USD 10.6 billion by 2026 from USD 7.9 billion in 2021, at a CAGR of 5.8%. ” The rising global demand for pharmaceuticals has fueled the growth of drug production, increasing the excipient consumption rate. The discovery of increasingly lipophilic APIs, macromolecules, and biological actives has created the need for well-evaluated excipients and the development of new ones. The currently used excipients may not be sufficient to support the newly discovered actives. As a result, demand has grown for newer, improved drugs, which calls for the development of new drug delivery systems...

テレヘルス＆テレメディシン（遠隔医療）の世界市場予測（～2027）：コンポーネント別、配信別、用途別、エンドユーザー別、地域別
HIT3542-22 / MarketsandMarkets / 2022年3月10日 / マーケッツアンドマーケッツ社は、世界のテレヘルス＆テレメディシン（遠隔医療）市場規模が、2022年878億ドルから2027年2,857億ドルまで年平均26.6％成長すると予測しています。本調査レポートは、テレヘルス＆テレメディシン（遠隔医療）の世界市場について調査し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、コンポーネント別（ソフトウェア＆サービス、ハードウェア）分析、配信別（クラウドベース、オンプレミス）分析、用途別（テレコンサルテーション、TeleICU、テレラジオロジー、テレストローク、テレダーマトロジー）分析、エンドユーザー別（提供者、支払者、患者、その他）分析、地域別分析、競争状況、企業情報など、以下の構成でまとめております。・イントロダクション・調査手法・エグゼクティブサマリー・プレミアムインサイト・市場概要・世界のテレヘルス＆テレメディシン（遠隔医療）市場規模：コンポーネント別（ソフトウェア＆サービス、ハードウェア）・世界のテレヘルス＆テレメディシン（遠隔医療）市場規模：配信別（クラウドベース、オンプレミス）・世界のテレヘルス＆テレメディシン（遠隔医療）市場規模：用途別（テレコンサルテーション、TeleICU、テレラジオロジー、テレストローク、テレダーマトロジー）・世界のテレヘルス＆テレメディシン（遠隔医療）市場規模：エンドユーザー別（提供者、支払者、患者、その他）...“The global telehealth & telemedicine market is expected to grow at a CAGR of 26.6% during the forecast period, to reach USD 285.7 billion by 2027 from an estimated USD 87.8 billion in 2022.” The key factors driving the growth of this market include the need to expand healthcare access, the growing prevalence of chronic diseases and conditions, a shortage of physicians, advancements in telecommunications, government support and raising awareness, and rising technology adoption in the wake of COVID-19. However, regional variations in regulations, fraud, and the use of social media for care providers will restrict the market growth during...

ATPアッセイの世界市場予測（～2027）：製品別、用途別、エンドユーザー別
AST7417-22 / MarketsandMarkets / 2022年4月7日 / マーケッツアンドマーケッツ社は、世界のATPアッセイ市場規模が2022年276百万ドルから2027年412百万ドルまで、年平均8.4％成長すると予想しています。本市場調査資料では、ATPアッセイの世界市場を広く調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品別（消耗品・付属品、機器）分析、用途別（汚染検査、疾病検査、創薬・開発）分析、エンドユーザー別（製薬・バイオテクノロジー企業、食品・飲料産業、病院・診断研究機関、学術・研究機関）分析、地域別分析、競争状況、企業情報などの項目を掲載しています。・イントロダクション・調査手法・エグゼクティブサマリー・プレミアムインサイト・市場概要・世界のATPアッセイ市場規模：製品別（消耗品・付属品、機器）・世界のATPアッセイ市場規模：用途別（汚染検査、疾病検査、創薬・開発）・世界のATPアッセイ市場規模：エンドユーザー別（製薬・バイオテクノロジー企業、食品・飲料産業、病院・診断研究機関、学術・研究機関）・世界のATPアッセイ市場規模：地域別...“The global ATP assays market is projected to reach USD 412 million by 2027 from USD 276 million in 2022, at a CAGR of 8.4%.” The growth of this market can largely be attributed to the increasing food safety concerns, growing demand for ATP assays in pharmaceutical & biotechnology companies, rising investments in pharmaceutical & biotechnology R&D, increasing prevalence of cancer and other chronic and infectious diseases, and the shift from culture-based tests to rapid tests. However, the high cost of instruments and inability to differentiate between extracellular and intracellular ATP are expected to restrain the growth of this market...

床研削盤の世界市場予測（～2027）：床種類別、機械構成別、エンドユーザー別、流通チャネル別、地域別
BC8080-22 / MarketsandMarkets / 2022年4月20日 / マーケッツアンドマーケッツ社は、世界の床研削盤市場規模が2022年303百万ドルから2027年356百万ドルまで、年平均3.3％成長すると予想しています。本市場調査資料では、床研削盤の世界市場を広く調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、産業動向、床種類別（大理石・石灰岩、コンクリート、花崗岩、木材）分析、機械構成別（シングルディスク、トライ・クワッドディスク、その他）分析、用途別（研削・研磨、除去、バフ研磨）分析、流通チャネル別（直接販売、専門店）分析、地域別分析、競争状況、企業情報などの項目を掲載しています。・イントロダクション・調査手法・エグゼクティブサマリー・プレミアムインサイト・市場概要・産業動向・世界の床研削盤市場規模：床種類別（大理石・石灰岩、コンクリート、花崗岩、木材）・世界の床研削盤市場規模：機械構成別（シングルディスク、トライ・クワッドディスク、その他）・世界の床研削盤市場規模：用途別（研削・研磨、除去、バフ研磨）...“The global floor grinding machines market size is projected to grow from USD 303 million in 2022 to USD 356 million by 2027, at a CAGR of 3.3% from 2022 to 2027.” The growth of the floor grinding machines market is attributed to their high demand in residential, commercial, and industrial sectors. Demand for commercial spaces such as offices, shopping malls, educational institutions and retail outlets will drive the demand for floor grinding machines for commercial purposes. Concrete floor grinding machines are not only used for grinding concrete floors but are also used for polishing marble and granite countertops. The...

メタゲノムシーケンスの世界市場予測（～2027）：製品・サービス別、ワークフロー別、技術別、用途別
BT7350-22 / MarketsandMarkets / 2022年4月4日 / マーケッツアンドマーケッツ社は、世界のメタゲノムシーケンス市場規模が、2022年19億ドルから2027年43億ドルまで年平均18.4％成長すると予測しています。本調査資料では、メタゲノムシーケンスの世界市場を調査対象とし、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品・サービス別（試薬＆消耗品、機器、サービス）分析、ワークフロー別（試料調製、シーケンス、データ処理・分析）分析、技術別（16S rRNA、ショットガンメタゲノム、全ゲノム、メタトランスクリプトミクス）分析、用途別（創薬、臨床診断、土壌微生物叢、環境、その他）分析、地域別分析、競争状況、企業情報などの項目を掲載しています。・イントロダクション・調査手法・エグゼクティブサマリー・プレミアムインサイト・市場概要・世界のメタゲノムシーケンス市場規模：製品・サービス別（試薬＆消耗品、機器、サービス）・世界のメタゲノムシーケンス市場規模：ワークフロー別（試料調製、シーケンス、データ処理・分析）・世界のメタゲノムシーケンス市場規模：技術別（16S...“The metagenomic sequencing market is expected to reach USD 4.3 billion by 2027 from USD 1.9 billion in 2022, at a CAGR of 18.4% during the forecast period.” Growth in the metagenomic sequencing market is mainly driven by continuous technological innovations in NGS platforms, increasing initiatives and funding from government & private bodies for large-scale sequencing projects, declining costs of genome sequencing, and the significant applications of metagenomics in various fields. “By technology segment, the shotgun metagenomic sequencing segment accounted for the fastest-growing segment of the metagenomic sequencing market” Based on technology, the metagenomic sequencing market is segmented into 16S...

◆H&Iグローバルリサーチ株式会社のお客様（例）◆